RecruitingPhase 2NCT05282550
Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone
RCT Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone (REST)
Sponsor
Johns Hopkins University
Enrollment
100 participants
Start Date
Feb 2, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
To investigate the effect of trazodone on sleep, hippocampal-dependent memory and hippocampal excitability. The investigators hypothesize that trazodone will improve total sleep time and proportion of time in Slow Wave Sleep (SWS).
Eligibility
Min Age: 55 Years
Inclusion Criteria8
- Mild Cognitive Impairment (MCI) as defined by Albert et al.2 including subjective memory complaint and/or objective evidence of memory problems;
- Clinical Dementia Rating (CDR) of 0.5 with a Memory Box score of \>=0.5;
- Evidence of sleep complaints with Pittsburgh Sleep Quality Index score of \>5 (a well-validated cutoff observed in \>40% of older persons);
- Memory performance \> 1.5 Standard Deviation (SD) below age-and education-matched control subjects on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) List Recall;
- Visual and auditory acuity adequate for neuropsychological testing;
- Good general health with no disease expected to interfere with the study;
- Able to have Magnetic Resonance Imaging (MRI) scan;
- Availability of knowledgeable informant (KI)
Exclusion Criteria14
- Less than 55 years of age to reduce likelihood of including individuals with frontotemporal dementia or non-dementia MCI;
- Too frail or medically unstable to undergo study procedures;
- Prior diagnosis of Obstructive Sleep Apnea (OSA) or evidence of moderate-to-severe OSA on baseline Home Sleep Test (HST) as evidenced by an apnea/hypopnea index of \>15;
- Dementia;
- Cognitive complaints and deficits better explained by other medical/neurologic conditions;
- Delirium;
- Allergic to trazodone;
- Taking sleep medications including trazodone;
- Current substance abuse;
- Current major depressive, manic, or acute psychotic episode;
- Prior diagnosis of significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol or represent alternate primary cause of memory problems beyond Alzheimer's Disease (AD) pathology:
- Lack of available KI;
- Prior diagnosis of Q wave T wave Corrected for heart rate (QTc) \> 470 msec (females) or \> 450 msec (males);
- Inability to provide informed consent
Interventions
DRUGTrazodone
50mg of trazodone administered for 4 weeks.
DRUGPlacebo
Placebo administered for 4 weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05282550
Related Trials
Virtual vs Physical Art Therapy for Anxiety, Psychological Well-being, and Sleep Quality in Colorectal Cancer Patients
NCT074646261 location
VR-PMR for Post-Burn Symptoms
NCT073172711 location
Sleep Promotion Program Primary Care
NCT062403251 location
Wellness App for Sleep Disturbance in Hematological Cancer Patients
NCT052949913 locations
A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications
NCT073804121 location